近日,恒瑞医药公司发布公告,其与葛兰素史克(GSK)达成一项总潜在金额高达125亿美元的License-out合作,覆盖一款处于临床阶段的呼吸系统创新药及多达11个处于非临床阶段的候选项目。这表明创新药对外授权交易持续火热,将极大地鼓舞创新药企和相关从业人员的热情和信心。与此同时,国家医保局召开医保支持创新药械系列座谈会第四场,旨在落实《支持创新药高质量发展的若干措施》,推动创新药高质量发展,更好...
Source Link近日,恒瑞医药公司发布公告,其与葛兰素史克(GSK)达成一项总潜在金额高达125亿美元的License-out合作,覆盖一款处于临床阶段的呼吸系统创新药及多达11个处于非临床阶段的候选项目。这表明创新药对外授权交易持续火热,将极大地鼓舞创新药企和相关从业人员的热情和信心。与此同时,国家医保局召开医保支持创新药械系列座谈会第四场,旨在落实《支持创新药高质量发展的若干措施》,推动创新药高质量发展,更好...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.